Standout Papers

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxalipla... 2010 2026 2015 2020 1.3k
  1. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study (2010)
    Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology

Immediate Impact

10 from Science/Nature 87 standout
Sub-graph 1 of 17

Citing Papers

Colorectal cancer
2024 Standout
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
2023 Standout
22 intermediate papers

Works of M. Rother being referenced

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
2010 Standout
Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining.
2010

Author Peers

Author Last Decade Papers Cites
M. Rother 1259 565 355 363 8 1.4k
Allert H. Vos 1325 532 324 312 11 1.6k
Yousif Abubakr 1068 480 179 330 7 1.2k
Yevhen Hotko 1197 592 307 276 26 1.4k
M. Elisa Vink-Börger 1266 524 484 351 9 1.6k
Joseph J. Schulz 1279 523 146 460 8 1.5k
Joe McKendrick 845 407 171 288 9 1.1k
Belguendouz Bendahmane 1053 417 259 290 16 1.2k
M. E. Vega-Villegas 931 542 177 224 17 1.2k
Claus-Christoph Steffens 946 467 161 303 18 1.1k
Alan Rong 825 366 262 233 26 1.0k

All Works

Loading papers...

Rankless by CCL
2026